

Table S4: Statistical analysis of clinical parameters for hospitalized patients treated with Casirivimab/Imdevimab. Missing data were excluded, causing different numbers for each parameter. Average \pm standard deviation is shown. For metric parameters, significance was determined using Student's T-test, Cross tables were analysed using Fisher's exact test. $p < 0.1$: +; $p < 0.05$: *; $p < 0.01$: **. Significance signs in "All" in the female table indicate significant difference to the male sex.

Parameter	All patients		
	All	untreated	treated
Number	315	90	225
Age	67.1 \pm 17.0	66.9 \pm 20.9	67.2 \pm 15.2
Symptoms			
Coughing (n/y)	146/156	52/31	94/125 **
% yes	51.7 %	37.3 %	57.1 %
Dyspnea (n/y)	207/95	44/39	163/56 **
% yes	31.5 %	44.0 %	25.6 %
Fatigue (n/y)	201/100	63/20	138/80 *
% yes	33.2 %	24.1 %	36.7 %
Pain (n/y)	214/87	67/16	147/71 *
% yes	28.9 %	19.3 %	32.6 %
Inappetenz (n/y)	248/54	71/12	177/42
% yes	17.9 %	14.5 %	19.2%
Loss of taste and smell (n/y)	278/23	79/4	199/19
% yes	7.6 %	4.8 %	8.7 %
Diarrhoea / vomiting (n/y)	263/39	74/9	189/30
% yes	12.9 %	10.8 %	13.7 %
Fever (n/y)	189/113	49/34	140/79
% yes	37.4 %	41.0 %	36.1 %
Temperature	37.3 \pm 1.0	37.3 \pm 1.0	37.3 \pm 1.0
Neurological Symptoms (n/y) % yes	282/20 6.6 %	78/5 6.0 %	204/15 6.8 %
Syncope (n/y)	280/22	73/10	207/12 +
% yes	7.3 %	12.0 %	5.5 %
Risk factors			
Hypertension (n/y)	129/178	39/47	90/131
% yes	58.0 %	54.7 %	59.3 %
Blood pressure systolic	127.7 \pm 20.1	124.9 \pm 22.4	128.5 \pm 19.3
Blood pressure diastolic	67.6 \pm 12.8	73.4 \pm 11.7	77.5 \pm 13.1
Cardiac frequency (1/min)	82.3 \pm 16.6	83.5 \pm 15.7	81.7 \pm 17.0
Diabetes (n/y)	232/75	62/24	170/51
% yes	24.4 %	27.9 %	23.1 %
Renal insufficiency (n/y)	248/58	67/19	181/39
% yes	19.0 %	22.1 %	17.7 %
COPD/Asthma (n/y)	241/65	65/21	176/44
% yes	21.2 %	24.4 %	20.0 %
Active malignoma (n/y)	279/28	79/7	200/21
% yes	9.1 %	8.1 %	9.5 %
Inactive malignoma (n/y)	292/14	80/5	212/9
% yes	4.6 %	5.9 %	4.1 %
Immunosuppression (n/y)	287/19	83/3	204/16
% yes	6.2 %	3.5 %	7.3 %

Obesity (n/y)	240/64	68/17	172/47
% yes	21.1 %	20.0 %	21.5 %
Heart disease (n/y)	208/98	56/30	152/68
% yes	32.0 %	34.9 %	30.9 %
Hypothyreosis (n/y)	261/45	69/16	192/29
% yes	14.7 %	18.8 %	13.1 %
Blood gas analysis			
pO ₂	10.0 ± 3.3	9.7 ± 4.5	10.2 ± 2.6
pCO ₂	4.7 ± 0.8	4.7 ± 0.8	4.7 ± 0.8
O ₂ -Saturation %	93.6 ± 4.9	92.3 ± 4.9	94.1 ± 4.8
Clinical chemistry			
Hemoglobin (mM)	8.3 ± 1.3	8.2 ± 1.2	8.3 ± 1.3
Leukocytes (Gpt/L)	6.9 ± 6.1	7.6 ± 4.4	6.6 ± 6.4
Lymphocytes (Gpt/L)	1.3 ± 1.5	1.3 ± 1.9	1.2 ± 1.2
Thrombocytes (Gpt/L)	200.8 ± 80.6	208.4 ± 90.3	197.6 ± 76.1
CRP (mg/L)	52.0 ± 57.9	69.7 ± 69.5	44.4 ± 50.4
proBNP (mg/mL)	2562 ± 4965	2543 ± 5348	2575 ± 4713
Troponin (ng/mL)	0.06 ± 0.20	0.08 ± 0.31	0.04 ± 0.11
Blood glucose (mM)	8.4 ± 11.1	9.8 ± 17.0	7.6 ± 4.2
Creatinin(μM)	121.9 ± 139.8	115.1 ± 115.0	124.8 ± 149.4
GFR (mL/min/1.73m ²)	69.7 ± 29.5	70.1 ± 33.8	69.5 ± 27.5
PCR (Ct)	24.8 ± 5.0	26.7 ± 4.9	24.0 ± 4.9
Hospitalization (d)	10.3 ± 9.9	14.4 ± 11.1	8.6 ± 8.9 **
Death (n/y)	276/33	71/16	205/17 *
% yes	10.7 %	18.3 %	7.7 %

Parameter	Female		
	All	untreated	treated
Number	169	52	117
Age	68.1 ± 17.0	66.8 ± 20.3	68.6 ± 15.5
Symptoms			
Coughing (n/y)	82/78	29/18	53/60
% yes	48.8 %	38.3 %	53.1 %
Dyspnea (n/y)	105/55	22/25	83/30 **
% yes	34.4 %	53.2 %	26.5 %
Fatigue (n/y)	103/56	32/15	71/41
	35.2 %	31.9 %	36.6 %
Pain (n/y)	111/48	35/12	76/36
% yes	30.2 %	35.5 %	32.1 %
Inappetenz (n/y)	127/33	40/7	87/26
% yes	20.6 %	14.9 %	23.0 %
Loss of taste and smell (n/y)	147/12	46/1	101/11
% yes	7.5 %	2.1 %	9.8 %
Diarrhoea / vomitting (n/y)	135/25	40/7	95/18
% yes	15.6 %	14.9 %	15.9 %
Fever (n/y)	100/60	27/20	73/40
% yes	37.5 %	42.6 %	35.4 %
Temperature	37.4 ± 1.0	37.2 ± 0.9	37.4 ± 1.0
Neurological Symptoms	148/12	44/3	104/9
(n/y) % yes	7.5%	6.4 %	8.0 %

Syncope (n/y)	147/13	40/7	107/6 +
% yes	8.1 %	14.9 %	5.3 %
Preexisting illness			
Hypertension (n/y)	72/91	22/27	50/64
% yes	55.8 %	55.1 %	56.1 %
Blood pressure systolic	127.6 ± 22.4	123.7 ± 24.7	129.1 ± 21.4
Blood pressure diastolic	76.2 ± 13.0	72.4 ± 12.4	77.6 ± 13.0 *
Cardiac frequency (1/min)	82.2 ± 16.0	83.1 ± 14.8	81.8 ± 16.6
Diabetes (n/y)	129/34	38/11	91/23
% yes	20.9 %	22.4 %	22.2 %
Renal insufficiency (n/y)	134/29	39/10	95/19
% yes	17.8 %	20.4 %	16.7 %
COPD/Asthma (n/y)	133/30	38/11	95/19
% yes	18.4 %	22.4 %	16.7 %
Active malignoma (n/y)	154/9 *	47/2	107/7
% yes	5.5 %	4.1 %	6.1 %
Inactive malignoma (n/y)	155/8	45/4	110/4
% yes	4.9 %	8.2 %	3.5 %
Immunosuppression (n/y)	150/13	48/1	102/12
% yes	8.0 %	2.0 %	10.5 %
Obesity (n/y)	122/41 +	36/13	86/28
% yes	25.2 %	26.5 %	24.6 %
Heart disease (n/y)	118/45 +	33/16	85/29
% yes	27.6 %	32.7 %	25.4 %
Hypothyreosis (n/y)	126/37 **	35/13	90/24
% yes	22.7 %	26.5 %	21.1 %
Blood gas analysis			
pO ₂	9.8 ± 2.4	9.1 ± 2.2	10.1 ± 2.4 **
pCO ₂	4.7 ± 0.8	4.7 ± 0.9	4.7 ± 0.8
O ₂ -Saturation %	93.6 ± 4.2	92.1 ± 4.0	94.3 ± 4.1 **
Clinical chemistry			
Hemoglobin (mM)	8.1 ± 1.2 +	8.0 ± 1.1	8.2 ± 1.3
Leukocytes (Gpt/L)	6.4 ± 3.4	7.3 ± 3.7	6.0 ± 3.2 *
Lymphocytes (Gpt/L)	1.1 ± 0.5	1.2 ± 0.5	1.1 ± 0.5
Thrombocytes (Gpt/L)	206.3 ± 73.0	219.2 ± 90.2	200.1 ± 62.5
CRP (mg/L)	44.7 ± 49.1 *	58.9 ± 59.6	37.7 ± 41.7 *
proBNP (mg/mL)	2400 ± 4497	2239 ± 4550	2503 ± 4505
Troponin (ng/mL)	0.04 ± 0.11	0.05 ± 0.09	0.03 ± 0.12
Blood glucose (mM)	8.9 ± 14.4	10.5 ± 22.1	7.8 ± 4.3
Creatinin(μM)	90.3 ± 64.1 **	94.3 ± 65.9	88.4 ± 63.4
GFR (mL/min/1.73m ²)	72.2 ± 28.8	71.0 ± 34.5	72.3 ± 25.7
Hospitalization (d)	11.0 ± 10.7	16.2 ± 11.9	8.8 ± 9.3 **
PCR (Ct)	25.2 ± 5.1	27.0 ± 5.1	24.3 ± 4.8 **
Death (n/y)	149/16	45/6	104/10
% yes	9.7 %	11.8 %	8.8 %

Parameter		Male	
	All	untreated	treated
Number	146	38	108
Age	66.1 ± 16.9	66.9 ± 22.0	65.8 ± 14.9
Symptoms			

Coughing (n/y)	64/78	23/13	41/65 *
% yes	54.9 %	36.1 %	61.3 %
Dyspnea (n/y)	102/40	22/14	80/26
% yes	28.2 %	38.9 %	24.5 %
Fatigue (n/y)	98/44	31/5	67/39 *
% yes	31.0 %	13.9 %	36.8 %
Pain (n/y)	103/39	32/4	71/35 *
% yes	27.5 %	11.1 %	33.0 %
Inappetenz (n/y)	121/21	31/5	90/16
% yes	14.8 %	13.9 %	15.1 %
Loss of taste and smell (n/y)	131/11	33/3	98/8
% yes	7.7 %	8.3 %	7.5 %
Diarrhoea / vomitting (n/y)	128/14	34/2	94/12
% yes	9.9 %	5.6 %	11.3 %
Fever (n/y)	89/53	22/14	67/39
% yes	37.3 %	38.9 %	36.8 %
Temperature	37.2 ± 1.0	37.0 ± 1.0	37.2 ± 1.1
Neurological Symptoms (n/y) % yes	134/8 5.6 %	34/2 5.6 %	100/6 5.7 %
Syncope (n/y)	133/9	33/3	100/6
% yes	6.3 %	8.3 %	5.7 %
Risk factors			
Hypertension (n/y)	57/87	17/20	40/67
% yes	60.4 %	54.1 %	62.6 %
Blood pressure systolic	127.7 ± 17.0	127.0 ± 18.1	127.8 ± 16.9
Blood pressure diastolic	77.0 ± 12.7	75.1 ± 10.3	77.5 ± 13.2
Cardiac frequency (1/min)	82.4 ± 17.6	84.3 ± 17.5	81.7 ± 17.7
Diabetes (n/y)	103/41	24/13	79/28
% yes	28.5 %	25.1 %	26.2 %
Renal insufficiency (n/y)	114/29	28/9	86/20
% yes	20.3 %	24.3 %	18.9 %
COPD/Asthma (n/y)	108/35	27/10	81/25
% yes	24.5 %	27.0 %	23.6 %
Active malignoma (n/y)	125/19	32/5	93/14
% yes	13.2 %	13.5 %	13.1 %
Inactive malignoma (n/y)	135/8	33/3	102/5
% yes	5.6 %	8.3 %	4.7 %
Immunosuppression (n/y)	137/6	35/2	102/4
% yes	4.2 %	5.4 %	3.8 %
Obesity (n/y)	118/23	32/4	86/19
% yes	16.3 %	11.1 %	18.1 %
Heart disease (n/y)	90/53	23/14	67/39
% yes	37.1 %	37.8 %	36.8 %
Hypothyreosis (n/y)	137/6	35/1	102/5
% yes	4.2 %	2.8 %	4.7 %
Blood gas analysis			
pO ₂	10.4 ± 4.1	10.5 ± 6.5	10.3 ± 2.8
pCO ₂	4.7 ± 0.8	4.7 ± 0.8	4.7 ± 0.8
O ₂ -Saturation %	93.4 ± 5.6	92.6 ± 6.1	93.8 ± 5.4
Clinical chemistry			
Hemoglobin (mM)	8.4 ± 1.4	8.4 ± 1.4	8.4 ± 1.4
Leukocytes (Gpt/L)	7.4 ± 8.1	8.0 ± 5.3	7.1 ± 8.9

Lymphocytes (Gpt/L)	1.4 ± 2.1	1.6 ± 3.0	1.4 ± 1.6
Thrombocytes (Gpt/L)	194.3 ± 88.6	192.7 ± 89.4	194.8 ± 88.7
CRP (mg/L)	60.7 ± 66.0	85.4 ± 80.1	51.6 ± 57.8 **
proBNP (mg/mL)	2808 ± 5638	2948 ± 6339	2695 ± 5117
Troponin (ng/mL)	0.08 ± 0.28	0.14 ± 0.48	0.06 ± 0.10
Blood glucose (mM)	7.9 ± 3.7	8.8 ± 4.2	7.3 ± 3.2 +
Creatinin(μM)	159.1 ± 187.9	153.5 ± 156.0	165.1 ± 199.4
GFR (mL/min/1.73m ²)	66.7 ± 30.2	68.7 ± 33.2	65.9 ± 29.1
PCR (Ct)	24.4 ± 5.0	26.2 ± 4.7	23.7 ± 5.0 *
Hospitalization (d)	9.4 ± 8.7	11.9 ± 9.5	8.5 ± 8.3 *
Death (n/y)	127/17	26/10	101/7 **
% yes	11.8 %	27.8 %	6.5 %